Global Human Milk Oligosaccharides (HMO) Market - 2023-2030

Human Milk Oligosaccharides The Global Human Milk Oligosaccharides (HMO) Market was valued at USD 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to USD 850.5 million by 2030. The market is growing at a CAGR of 20.1% during the forecast period 2024-2031.

HMOs are increasingly being incorporated into infant formula to mimic the composition and function of human breast milk. HMOs are recognized as an essential component of human milk and play a crucial role in infant health and development. Manufacturers are investing in research and development to optimize HMO composition in infant formula, enhancing its similarity to breast milk. This trend is driven by the desire to provide infants with HMOs' functional benefits even when breastfeeding is not possible.

There is a growing consumer preference for functional ingredients that offer health benefits. HMO, a breast milk Components, are considered bioactive compounds with various physiological functions, including supporting the development of healthy gut microbiota, boosting the immune system, and promoting cognitive development.

Market Dynamics

Growing Demand for Infant Formula Driving the Growth of the Human Milk Oligosaccharides (HMO) Market

The European Regional Development Fund (ERDF) in the Atlantic Area Programme has stated that baby foods are specifically formulated to fulfill the dietary requirements of infants and children between the ages of 0 and 36 months. Infant formula serves as a substitute for breast milk when breastfeeding is not possible or preferred. To bridge the nutritional gap between breast milk and formula, manufacturers are incorporating HMOs into their products. HMOs are naturally occurring in breast milk and are considered beneficial for infant health. The demand for breast milk substitutes containing HMOs is driving the growth of the HMO market.

HMOs offer various nutritional benefits to infants. They support immune system development, promote gut health, and act as prebiotics, nourishing beneficial gut bacteria. Research has also indicated their positive impact on cognitive development. With growing awareness among healthcare professionals and parents about these benefits, there is an increasing demand for infant formula enriched with HMOs. Parents are seeking products that provide optimal nutrition for their infants, and the inclusion of HMOs addresses this demand.

The Rising Global Population is Driving the Market Growth Of Human Milk Oligosaccharides (HMO)

The global population is experiencing an overall increase in birth rates. According to United Nations, the World population is projected to reach 9.8 billion in 2050 and 11.2 billion in 2100. As the number of births rises, there is a greater demand for infant nutrition products, including those enriched with HMOs. HMOs are naturally occurring in breast milk and are recognized for their health benefits for infants. The higher birth rates lead to increased consumption of infant formula and other infant nutrition products containing HMOs, thereby driving the growth of the HMO market.

Urbanization is a global phenomenon, with more people residing in urban areas. Urban lifestyles often pose challenges for breastfeeding, such as limited maternity leave, higher rates of maternal employment, and less supportive breastfeeding environments. Consequently, there is a greater reliance on breast milk substitutes like infant formula. To address the nutritional needs of infants who are not breastfed, manufacturers are incorporating HMOs into their formula products. The growing urban population contributes to the demand for HMO-based infant formula, driving the growth of the HMO market.

Cost and Production Challenges Can Restrain the Growth of the Human Milk Oligosaccharides (HMO) Market

The production of HMOs is a complex and resource-intensive process. HMOs are typically produced through microbial fermentation or chemical synthesis, both of which require specialized equipment, expertise, and raw materials. These factors contribute to the high production costs of HMOs. The elevated costs are ultimately passed on to consumers, making HMO-based products more expensive compared to traditional infant formula or other nutritional products. The higher price point can limit the affordability and accessibility of HMOs, potentially restricting their widespread adoption and market growth.

Producing HMOs at scale while maintaining high purity and consistency can be challenging. The production processes require optimized fermentation or synthesis conditions, which may be difficult to achieve consistently. Scaling up production without compromising quality and yield can be complex and costly. Inefficient production processes and challenges in scaling up can limit the availability and quantity of HMOs in the market, hindering market growth.

Market Segmentation Analysis

The global human milk oligosaccharides (HMO) market is segmented based on product, type, application, and region.

Abundance of 2'-Fucosyllactose (2'FL) in Human Milk

The global human milk oligosaccharides (HMO) market has been segmented by products into Lacto-N-neotetraose (LNnT), Lacto-N-tetraose (LNT), 2'-Fucosyllactose (2'FL), 3'-Fucosyllactose (3'FL), 3'-Sialyllactose (3'SL), 6'-Sialyllactose (6'SL), and Others

In 2022, the 2'-Fucosyllactose (2'FL) had the highest revenue share in the human milk oligosaccharides (HMO) market. 2'-Fucosyllactose is one of the most abundant HMOs naturally present in human breast milk. It is estimated that 2'FL is found in significant quantities in over 80% of human breast milk samples. Its presence in breast milk highlights its importance for infant nutrition.

2'FL is known for its potential health benefits, including its prebiotic properties, which promote the growth of beneficial gut bacteria, such as Bifidobacteria. It also acts as a receptor analog for specific pathogens, helping to inhibit their attachment to the intestinal lining. These properties make 2'FL a valuable component in infant formula and other nutrition products.

Market Geographical Share

Growing Population in Asia-Pacific Region

In 2022, Asia -Pacific had the highest revenue share of the human milk oligosaccharides (HMO) market. The Asia Pacific region is home to a large and rapidly growing population. According to United Nations Population Fund, with 4.3 billion inhabitants, or 60% of the world's population, the Asia and Pacific region contains China and India as its two most populous nations. With a considerable number of births occurring in this region, there is substantial demand for infant nutrition products, including those enriched with HMOs.

Awareness about the benefits of HMOs in infant nutrition is growing in the Asia Pacific region. Healthcare professionals, as well as parents, are becoming more informed about the advantages of HMOs in supporting infant health, immune system development, and gut health. This increasing awareness has contributed to the adoption of HMO-based products in the region.

Market Major Players

The major global players include Elicityl SA, Medolac Laboratories, Inbiose NV, Glycosyn, ZuChem, Jennewein Biotechnologie GmbH, Glycom A/S, Dextra Laboratories Limited, DuPont Nutrition & Health, Nestlé Health Science

COVID-19 Impact

A robust and diverse food supply is an essential part of the health and nutrition response to COVID-19. The demand for nutraceuticals & functional foods is expected to witness an upward surge owing to consumers opting for immunity-boosting supplements during the COVID-19 pandemic. The use of HMOs in dietary supplements offers benefits such as immune support, protection against bacterial and viral infections, digestive health Human Milk Oligosaccharides (HMO), and brain function support. Furthermore, a decline in the consumption of poultry, meat, and seafood products across the globe is expected to increase the demand for plant and animal-based protein supplements shortly.

Key Developments
• In November 2022, Kyowa Hakko Bio Co. Ltd (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), built a human milk oligosaccharide (HMO) production plant at its Thai affiliate, Thai Kyowa Biotechnologies Co, Ltd.
• In October 2022, Friesland Campinas's 2’-fucosyllactose trademarked Aequival was authorized by Australia’s and New Zealand’s authorities for use in infant milk formula
• In April 2020, Royal DSM, a global science-based company in Nutrition, Health, and Sustainable Living, acquired Glycom, one of the suppliers of Human Milk Oligosaccharides (HMO) for an enterprise value of €765 million.

Why Purchase the Report?
• To visualize the global human milk oligosaccharides (HMO) market segmentation based on product, type, application, and region understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous human milk oligosaccharides (HMO) market-level data points all for segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The Global Human Milk Oligosaccharides (HMO) Market Report Would Provide Approximately 61 Tables, 63 Figures, and 102 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies